Navigation Links
Access Pharmaceuticals MuGard Added to Nationally Ranked Children's Hospital of Colorado Pharmacy Formulary
Date:2/16/2012

DALLAS and NEW YORK, Feb. 16, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that Children's Hospital of Colorado has added MuGard to its hospital pharmacy formulary.  Children and young adults undergoing cancer treatment will now have direct access to MuGard from the first day of cancer treatment to manage oral mucositis, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.

Commenting on the significance of the event, Frank Jacobucci, Vice President Sales and Marketing, Access Pharmaceuticals, Inc. said, "Having Children's Hospital of Colorado evaluate MuGard and determine that it has tremendous benefit for their patients undergoing cancer therapy is an important milestone for Access.  There are roughly 5800 hospitals in the US with approximately 37 million admissions annually.  The hospital inpatient market is very large and currently there is no meaningful intervention for these patients to prevent or treat oral mucositis. The inclusion of MuGard on Children's Hospital formulary will allow providers and patients to have access to MuGard and potentially eliminate oral mucositis as a side effect of anticancer treatment regimens."

Top ranked consecutively on the U.S. News & World Report Best Children's Hospital's honor rankings since inception, Children's Hospital Colorado garners local, regional, national and international respect for its treatment and care of children, adolescents and young adults with cancer and non-malignant blood diseases, such as hemophilia and sickle cell anemia. The Center is the o
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 ... senkt die Leistungsfähigkeit enorm. Es ist schwierig konzentriert ... wacht zum falschen Zeitpunkt in einem Hotelzimmer auf, ... später, nach Hause zurückgekehrt, fühlt man sich  oft ... oder dem Partner etwas zu unternehmen oder bei ...
(Date:5/26/2015)... , May 26, 2015  The National Association of ... pleased to announce that general availability for the .pharmacy ... pharmacies and pharmacy-related entities may apply for .pharmacy domain ... launched in 2014, and NABP has approved more than ... prior limited registration periods. NABP created the .pharmacy TLD ...
(Date:5/26/2015)... Mass. , May 26, 2015  Haemonetics Corporation ... Gould , Vice President, Investor Relations, will present at ... Boston on June 4 th , 2015 ... may access Mr. Gould,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
Breaking Medicine Technology:Jetlag schneller überwinden! Spitzen-Athleten wissen wie: Doppelt so schnell voll leistungsfähig sein mit innovativer Technik 2Jetlag schneller überwinden! Spitzen-Athleten wissen wie: Doppelt so schnell voll leistungsfähig sein mit innovativer Technik 3Jetlag schneller überwinden! Spitzen-Athleten wissen wie: Doppelt so schnell voll leistungsfähig sein mit innovativer Technik 4General Availability for .Pharmacy Domain Names Begins June 3, 2015 2
... Pharmatek Laboratories, Inc., a premier contract development and ... it has added spray drying to its drug ... a Buchi B-290 Mini Spray Dryer for formulation ... can be used for both oral and parenteral ...
... April 25, 2011 Stereotaxis, Inc. (NASDAQ: STXS ... following investor conferences during May 2011: The ... Kaminski, President and Chief Executive Officer of Stereotaxis, is scheduled ... 3, 2011 at 4:10 p.m. ET. The JMP Securities ...
Cached Medicine Technology:Pharmatek Laboratories Adds Spray Drying to Drug Development Services 2Stereotaxis to Present at Upcoming Investor Conferences 2Stereotaxis to Present at Upcoming Investor Conferences 3
(Date:5/27/2015)... May 27, 2015 The Case Management ... highest honor, the CMSA Lifetime Achievement Award, to Anne ... on Thursday, June 25th at the association’s 25th Annual ... Orlando, Florida. , The CMSA Board of Directors awards ... has made a significant contribution to practice of case ...
(Date:5/27/2015)... Connecticut (PRWEB) May 27, 2015 This year, ... mental health awareness campaign and encouraging those affected to seek ... on Mental Health (NAMI), one in five children, ages ... mental illness. Additionally, 50% of all cases of mental illness ... is suggesting, it is essential to seek help before reaching ...
(Date:5/27/2015)... Rosa Ca (PRWEB) May 27, 2015 ... University of Texas Southwestern Medical Center at Dallas some ... tunnel syndrome. Both CTS and migraine headache apparently also ... women, in incidents of obesity, people with a history ... be less common in Asians, and CTS in particular ...
(Date:5/26/2015)... Avid Collector, Andrew Hawley from ... Jimi Hendrix January 11-23, 1969 psychedelic German concert tour ... of Hendrix for this concert poster tour blank. ... known as the Hendrix with wired hair concert ... days. The tour started at the Musikhalle in ...
(Date:5/26/2015)... 26, 2015 Degeneration of the white ... of specific types of Alzheimer’s disease (AD), including early-onset ... in the journal Radiology. , “Alzheimer’s is a ... of the study conducted at the Neuroimaging Research Unit, ... matter damage has a central role in how the ...
Breaking Medicine News(10 mins):Health News:CMSA to Present Prestigious Lifetime Achievement Award to Anne Llewellyn RN-BC, MS, BHSA, CCM, CRRN 2Health News:The Glenholme School Observes Mental Health Awareness Month 2Health News:The Glenholme School Observes Mental Health Awareness Month 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 2Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 4Health News:Avid Collector from Vintage Rock Posters Announces His Search for Original Jimi Hendrix January 11-23, 1969 Psychedelic German Concert Tour Posters 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 3
... the most efficient radiation dose to pregnant patients with ... fetus, according to a study performed at SUNY ... , Simulated pulmonary and pelvic studies were performed ... range for fetal exposure using CT scanners. "The 64-slice ...
... may start drinking at a later age -- which may, ... new study suggests. , The findings, published in the May ... Drugs , underscore the important role parents play in the ... the age at which kids start drinking is a key ...
... Hospital at The University of Texas M. D. Anderson ... the growth of neuroblastoma, a childhood brain cancer. The ... at the 22nd annual meeting of the American Society ... the Children,s Cancer Hospital at M. D. Anderson, presented ...
... added the use of Mild Hyperbarics to drug and alcohol treatment program ... hyperbarics is not generally associated with drug and alcohol treatment in the ... services that meet the needs of the person in mind, body and ... ...
... Valeant Pharmaceuticals (NYSE: VRX ) today announced ... IIb dose-finding clinical trial for taribavirin, a prodrug of ... chronic hepatitis C in conjunction with a pegylated interferon, ... Study of Liver (EASL) 44th Annual Meeting in Copenhagen, ...
... at risk for developing condition , , THURSDAY, April 23 (HealthDay ... up to six times more likely to develop the disease ... and Prevention researchers. , They analyzed data on 1,500 adults, ... average, moderate or high risk of asthma based on the ...
Cached Medicine News:Health News:64-slice CT: Most dose efficient for evaluating pregnant patients with possible pulmonary emboli 2Health News:Good relationship with parents may prevent teen drinking problems 2Health News:Novel cancer drug reduces neuroblastoma growth by 75 percent 2Health News:G & G Holistic Addiction Treatment Uses Innovative Use of Oxygen Therapy Which Restores Mind and Body in Drug Rehab 2Health News:G & G Holistic Addiction Treatment Uses Innovative Use of Oxygen Therapy Which Restores Mind and Body in Drug Rehab 3Health News:Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting 2Health News:Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting 3Health News:Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting 4Health News:Family History of Asthma Boosts Odds Almost 6 Times 2
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
Medicine Products: